Loading…
Uses biomarker-based patient selection to develop precision psychiatric drugs matched to specific patient subtypes.
Uses biomarker-based patient selection to develop precision psychiatric drugs matched to specific patient subtypes.
Pre-revenue: it sells nothing, and trial costs are paid from cash raised since its early-2024 listing. Each drug is tested only in patients whose brain-activity or other markers match, so the results of those mid-stage depression trials, not sales, decide the company's course.
Moat: narrow (data, process know-how). Proprietary biomarker/EEG-based patient stratification aims to improve historically poor psychiatric trial success rates.
Headquarters: Los Altos, California, US · Founded: 2019 · Employees: 68
Size Alto Neuroscience (ANRO) is a United States Health Care company (Biotechnology) with a market value of $987M, the 2256th largest of 3,117 United States companies the cockpit tracks. Shares closed at $25.16 on 6 Nov 2026.
Performance Over six months the shares gained 3.7%, against -10.9% for the median peer and -1.1% for the United States market (cap-weighted) — 4th highest of 20 in its peer set.
Short interest Short interest is 13.3% of the free float (15 Oct 2026).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$705,000 | -$661,000 | -$502,000 | -$373,000 | -$342,000 |
| EBITDA | -$87.6M | -$65.7M | -$68.1M | -$37.4M | -$28.9M |
| Net income | -$84.2M | -$63.2M | -$61.4M | -$36.3M | -$27.7M |
| Free cash flow | -$68.8M | -$51.8M | -$49.5M | -$33.9M | -$21.1M |
| Capital expenditure | $556,000 | $24,000 | $2.08M | $470,000 | $732,000 |
| Total debt | $23.3M | $24.0M | $16.9M | $151M | $82.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Alto Neuroscience ANRO | $987M | +4% | n/a | n/a | n/a | n/a |
| Neurocrine Biosciences NBIX | $16.7B | +8% | +38% | 25% | 4.4× | -1.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ANRO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.7% | -4.6% | 6th highest of 21 |
| 6-month return | +3.7% | -10.9% | 4th highest of 20 |
| Distance from 52-week high | -32.9% | -41.7% | 5th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alto Neuroscience ANRO | United States | $987M | +4% | n/a | n/a | n/a | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $995M | -11% | 0% | 22% | 4.7× | 11.1% | +2.3% |
| Changchun BCHT Biotechnology 688276.SS | China | $1.00B | -11% | +2% | -29% | 10.0× | n/a | n/a |
| China Animal Husbandry Industry 600195.SS | China | $960M | -17% | +1% | 2% | 1.4× | 6.6% | +4.4% |
| Jade Biosciences JBIO | United States | $958M | -42% | n/a | n/a | n/a | n/a | n/a |
| Innovita Biological Technology 688253.SS | China | $1.02B | -4% | -28% | 11% | 16.3× | 42.9% | -16.6% |
| Verastem VSTM | United States | $1.02B | +72% | +3,996% | -183% | 11.1× | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $927M | -54% | n/a | -108% | 26.5× | n/a | n/a |
| Odyssey Therapeutics ODTX | United States | $924M | n/a | -33% | -5,415% | 208.9× | n/a | n/a |
| Inventiva IVA.PA | France | $912M | -29% | -100% | -307,063% | 14,560.9× | n/a | n/a |
| Janux Therapeutics JANX | United States | $1.08B | +24% | +5,367% | -598% | 5.3× | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $902M | -45% | -84% | -633% | 11.1× | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $892M | -14% | +16% | -18% | 4.3× | n/a | n/a |
| Daan Gene 002030.SZ | China | $1.11B | -9% | +1% | -81% | 8.4× | 5.7% | -32.3% |
| GNI 2160.T | Japan | $866M | -29% | +10% | -24% | 5.7× | n/a | n/a |
| MeiraGTx MGTX | United States | $864M | -8% | +948% | 46% | 2.1× | -9.9% | +39.2% |
| Syndax Pharmaceuticals SNDX | United States | $859M | -56% | +160% | -62% | 3.5× | n/a | n/a |
| Peptidream 4587.T | Japan | $856M | -10% | +1% | -25% | 6.6× | n/a | n/a |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.14B | -10% | -24% | -2% | 3.2× | 16.4% | -5.8% |
| Prime Medicine PRME | United States | $843M | +45% | -18% | -4,825% | 211.3× | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.17B | -36% | n/a | -838% | 39.3× | n/a | n/a |